Solid Tumor Clinical Trials

104 studies are recruiting for solid tumor in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

   GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   11 in total

   Run by

   Georgiamune Inc

   See if you can join NCT06425926 on ClinicalTrials.gov

2. A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

   Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05859074 on ClinicalTrials.gov

3. SMP-3124LP in Adults With Advanced Solid Tumors

   An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Cedars Sinai Medical Center, Los Angeles, California

   Locations

   12 in total

   Run by

   Sumitomo Pharma America, Inc.

   See if you can join NCT06526819 on ClinicalTrials.gov

4. A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

   The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monothera…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Los Angeles, Los Angeles, California

   Locations

   15 in total

   Run by

   PAQ Therapeutics, Inc.

   See if you can join NCT06797336 on ClinicalTrials.gov

5. Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

   The goal of this clinical research study is to learn about the safety and effects of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07382544 on ClinicalTrials.gov

6. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #67, Phoenix, Arizona

   Locations

   122 in total

   Run by

   Exelixis

   See if you can join NCT05176483 on ClinicalTrials.gov

7. Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

   This is an open-label phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy following lymphodepleting conditioning with or without local tumor ablation for pediatric and adult patients w…

   Stage

   Phase 1

   Ages

   1 to 70

   Site

   Children's National Hospital, Washington D.C., District of Columbia

   Run by

   Children's National Research Institute

   See if you can join NCT05238792 on ClinicalTrials.gov

8. A Study of ASP3082 in Adults With Advanced Solid Tumors

   This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   66 in total

   Run by

   Astellas Pharma Inc

   See if you can join NCT05382559 on ClinicalTrials.gov

9. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

   This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   42 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT04198766 on ClinicalTrials.gov

10. A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

    This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania

    Locations

    14 in total

    Run by

    Chugai Pharmaceutical

    See if you can join NCT05907980 on ClinicalTrials.gov

11. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

    Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesench…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UAB Comprehensive Cancer Center, Birmingham, Alabama

    Locations

    41 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT04939610 on ClinicalTrials.gov

12. Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

    This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary an…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    CBCC Global Research Site 001, Scottsdale, Arizona

    Locations

    9 in total

    Run by

    Alyssum Therapeutics

    See if you can join NCT06234098 on ClinicalTrials.gov

13. Imaging of Solid Tumors Using 18F-TRX

    This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumor…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Rahul Aggarwal

    See if you can join NCT06942104 on ClinicalTrials.gov

14. Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol

    The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic data may relate to cancer diagnosis and response to treatment, and to identify factors that may lead…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05390827 on ClinicalTrials.gov

15. The Intersection of Oncology Care and Worker Well-Being

    The goals of this study will be a greater understanding of cancer patients' well-being experience through the care/treatment continuum. An important aspect of the study is an understanding of work- and treatment-related challenges experienced by low-income men, many of whom will be Latino. At the 1…

    Stage

    Not phased

    Ages

    21 to 70

    Site

    University of Colorado Anschutz Medical Campus, Aurora, Colorado

    Run by

    University of Colorado, Denver

    See if you can join NCT05250284 on ClinicalTrials.gov

16. A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

    This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site-111, Newport Beach, California

    Locations

    17 in total

    Run by

    Biohaven Therapeutics Ltd.

    See if you can join NCT06874335 on ClinicalTrials.gov

17. Implementation of an Oral Chemotherapy Adherence Intervention

    The goal of this study is to evaluate the effectiveness and usability of a newly developed oral anticancer agent adherence program implemented across 6 cancer clinics (two academic, two urban, and two rural). The study will include 160 adult participants with either solid tumors or hematologic mali…

    Stage

    Not phased

    Ages

    21 and older

    Site

    UNC Chapel Hill, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06989489 on ClinicalTrials.gov

18. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back …

    Stage

    Phase 1

    Ages

    0 to 17

    Site

    Call for Information (Investigational Site 0019), Aurora, Colorado

    Locations

    16 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT02332668 on ClinicalTrials.gov

19. A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

    The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal can…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber/Massachusetts General Hospital, Inc, Boston, Massachusetts

    Locations

    9 in total

    Run by

    PAQ Therapeutics, Inc.

    See if you can join NCT07300150 on ClinicalTrials.gov

20. Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

    The purpose of this study is to translate and tailor for Latinx participants a program called Communicating with Oncology Nurses about Values from the Outset (CONVO). In CONVO, routine cancer care for each participant includes a discussion between the nurse and participant about the participant's h…

    Stage

    Not phased

    Ages

    21 and older

    Site

    MSK at Ralph Lauren (All Protocol Activities), New York, New York

    Locations

    5 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04942717 on ClinicalTrials.gov

21. High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis

    This trial applies a uniform approach to re-irradiation for planning and diagnostic image fusion, dose summation, dose calculations, and follow up for tumor control and detailed toxicity analysis of serial Organs At Risk (OARs). Serial organs include named arteries and nerves, spinal cord, and gast…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Froedtert Hospital, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT05301101 on ClinicalTrials.gov

22. A Study of PYX-201 in Advanced Solid Tumors

    The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    29 in total

    Run by

    Pyxis Oncology, Inc

    See if you can join NCT05720117 on ClinicalTrials.gov

23. A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

    This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]); and the dose expansion stage is to evaluate the preliminary antitumor act…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Exelixis Clinical Site #5, San Francisco, California

    Locations

    11 in total

    Run by

    Exelixis

    See if you can join NCT06952010 on ClinicalTrials.gov

24. A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

    This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors. The study will include …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Christiana Care Health System - Newark- Site Number : 8400011, Newark, Delaware

    Locations

    22 in total

    Run by

    Sanofi

    See if you can join NCT05584670 on ClinicalTrials.gov

25. Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

    This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.

    Stage

    Not phased

    Ages

    Up to 30

    Site

    Childrens Hospital of Colorado, Aurora, Colorado

    Locations

    6 in total

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT06579469 on ClinicalTrials.gov